Loblaw Companies Limited (TSX: L) turned in a stronger fourth quarter, but the stock still opened lower as investors weighed a solid earnings beat against a busy investment calendar and a valuation that already assumes steady execution.
In early trading, Loblaw shares were indicated around C$65.42, down C$2.10 or 3.11% on the day. The move followed a prior close near C$67.52, with the day’s range hovering roughly between C$64.63 and C$66.10. Over the past 52 weeks, the stock has traded from about C$43.78 to C$68.94, keeping it closer to the upper end of its annual band even after the pullback.
Q4 profit climbs as revenue rises on an extra week
Loblaw said profit available to common shareholders rose to C$656 million, or 55 cents per diluted share, for the 13-week period ended Jan. 3. A year earlier, the company reported C$462 million, or 38 cents per diluted share, in a fourth quarter that included 12 weeks. On an adjusted basis, Loblaw reported 67 cents per diluted share, up from 55 cents a year earlier.
Revenue increased to C$16.38 billion from C$14.73 billion, supported by the additional week. On a 12-week comparable basis, Loblaw said revenue advanced 3.5%, a pace that signals resilient demand even as consumers continue to trade off value and convenience across banners.
Food and drug retail trends show a split in momentum
Same-store sales in the food business rose 1.5%, a steadier read that aligns with a mature, high-frequency category where share gains can be incremental and competitive intensity is constant. The drug retail side moved faster, with same-store sales up 3.9%.
Inside pharmacy, the standout was health-care services. Pharmacy and health-care services same-store sales grew 5.6%, while front-store same-store sales increased 2.2%. The mix matters because services-led growth tends to support repeat visits and higher loyalty over time, reinforcing the strategic importance of Shoppers Drug Mart/Pharmaprix beyond traditional retail shelf economics.
Guidance points to earnings outpacing sales
Chief executive Per Bank said the company was pleased with another year of consistent operational and financial performance, emphasizing Loblaw’s push to meet customers where they need it most. Looking ahead, Loblaw said it expects its retail business to grow earnings faster than sales, while adjusted net earnings per common share are projected to post high single-digit growth.
That outlook can be read as a signal of continued discipline in cost control and operational efficiency, particularly as the company invests in store growth and supply chain upgrades. For investors, it also frames the near-term narrative: performance has to stay steady enough for higher capital spending to translate into stronger long-run returns.
A $2.4B spending plan accelerates expansion and modernization
Loblaw recently outlined plans to spend C$2.4 billion this year to expand and renovate its store network and build out supply chain capabilities. The company expects to open 70 new stores in 2026, including 34 new Shoppers Drug Mart/Pharmaprix pharmacies and care clinics and 31 new No Frills and Maxi stores. Alongside new locations, Loblaw plans renovations at 191 stores and continued progress on a new automated distribution centre in Caledon, Ontario.
The investment is part of a broader five-year plan to deploy C$10 billion through 2030. For a retailer built on scale and repeat traffic, that level of capital commitment is a statement: Loblaw is betting that convenience, discount formats, and health services can keep expanding even as consumers remain price-sensitive.
Stock metrics highlight a defensive profile, with valuation in focus
On the tape, Loblaw’s market footprint remains substantial, with an indicated market capitalization around C$77.27 billion. The stock’s beta near 0.47 underscores a more defensive trading profile relative to the broader market, a typical trait for essential retail and pharmacy names.
At the same time, valuation sits at levels that can amplify reactions to earnings prints. With a trailing P/E around 31.91 and trailing EPS around 2.05, expectations can feel less forgiving if growth moderates. Income support remains modest, with a forward dividend and yield shown around 0.55 and 0.82%, respectively. A one-year target estimate near C$66.27 sits close to the current price level, reinforcing the idea that near-term upside may require either stronger-than-expected execution or a shift in sentiment.
For readers tracking the official results release and corporate detail, Loblaw’s investor site provides the company’s reporting and updates in full context via Loblaw’s investor relations page.
Takeaway
Loblaw delivered the kind of quarter defensive investors typically want to see: higher profit, higher revenue, and a pharmacy services engine that continues to outgrow the core grocery base. The stock’s drop alongside the beat suggests the market is paying as much attention to valuation and the next phase of capital deployment as it is to the quarter that just closed. With a multi-year investment program now moving into a more active buildout, the company’s ability to keep earnings growth running ahead of sales will remain the key thread investors watch.
